Vaccine Side Effects, also known as adverse events following immunization (AEFI), are potential reactions that may occur after receiving a vaccine. It's important to note that most vaccine side effects are mild and temporary, such as soreness at the injection site, low-grade fever, or mild fatigue. These reactions are typically short-lived and resolve on their own without any long-term consequences. However, vaccines, like any medical intervention, can occasionally cause more serious side effects, although these are rare. Severe allergic reactions, known as anaphylaxis, can occur shortly after vaccination but are extremely rare, occurring in approximately 1 in every million vaccine doses administered. Symptoms of anaphylaxis may include difficulty breathing, swelling of the face or throat, rapid heartbeat, and dizziness, and require immediate medical attention.
Other rare but serious side effects associated with specific vaccines include febrile seizures, Guillain-Barré Syndrome (GBS), and acute disseminated encephalomyelitis (ADEM). These adverse events are closely monitored by public health authorities and vaccine safety surveillance systems to detect any potential signals or patterns and ensure the ongoing safety of vaccines. It's essential to emphasize that the benefits of vaccination far outweigh the risks of potential side effects. Vaccines have been rigorously tested in clinical trials to ensure their safety and efficacy before being approved for use. Additionally, extensive post-marketing surveillance systems continuously monitor vaccine safety to detect and investigate any adverse events that may occur after vaccination. The vast majority of vaccine side effects are mild and transient, and the risk of serious adverse events is extremely low. The benefits of vaccination in preventing serious and potentially life-threatening diseases, reducing the spread of infectious pathogens, and protecting individuals and communities far outweigh the risk of adverse events.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : Targeting resistance: New 4-substituted pyrazolidine and isoxazolidine as antibiotics with interesting antimicrobial activities
Yousfi Tarek, Nationale Research for Biotechnology Research Center, Algeria